This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

RCT of Russian IDU Peer Network HIV Prevention Intervention - 1

This study has been completed.
National Institute on Drug Abuse (NIDA)
Johns Hopkins University
Information provided by (Responsible Party):
Carl Latkin, Johns Hopkins Bloomberg School of Public Health Identifier:
First received: September 16, 2005
Last updated: May 11, 2016
Last verified: May 2016
The purpose of this study is to conduct a randomized controlled trial to assess the efficacy of a peer-educator intervention focused on injection drug users and their drug and sexual networks. We expect that participants who receive the intervention will demonstrate a reduction in the rate of HIV infection and HIV risk behaviors and members of their risk network will also demonstrate reductions in risk behaviors compared to those in the control group.

Condition Intervention Phase
HIV Infections Behavioral: Peer mentor intervention Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Randomized Controlled Trial of Russian IDU Peer Network HIV Prevention Intervention

Resource links provided by NLM:

Further study details as provided by Carl Latkin, Johns Hopkins Bloomberg School of Public Health:

Primary Outcome Measures:
  • Incident number of HIV Infections in social networks [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Self reported risk behaviors: entry into drug treatment, cessation of drug use [ Time Frame: 1 year ]
  • Self reported risk behaviors: number of sex partners, freq of condom use [ Time Frame: 3 months ]

Enrollment: 400
Study Start Date: October 2003
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: experimental
social network
Behavioral: Peer mentor intervention
groups sessions, 8
No Intervention: control
testing and counseling

Detailed Description:

Intravenous drug use (IDU) is driving the HIV epidemic in Russia; over 90% of all HIV-1 infections have occurred within communities of IDUs. In St. Petersburg (population 5 million), the prevalence of HIV infection in IDUs (estimated population 100,000) leapt from 4% in 1999 to 12% in 2000. At present there are an estimated 5-7 million IDUs, a four-fold increase since the end of the Soviet Union. In St. Petersburg, there has been a three-fold increase in regular IDUs and a nine-fold increase in teenage IDUs during the past five years.

The intervention to be tested in this study draws upon theoretical and empirical evidence suggesting that peer educator programs can have significant effects on the risk-related behaviors of both the educators and the peers whom they educate. Providing peer educator training to IDUs may efficiently cultivate sustainable protective behavioral norms related to injection and sexual risk among the IDU educators' social networks. Prior studies have demonstrated that peer educator programs can realize such normative changes, and it is hypothesized in this study that these normative changes will be reflected in significant reductions in the rates of HIV transmission among the peer educators and the members of their social networks.

Comparison condition: Informed by the Centers for Disease Control model of best practice" standard of care of HIV testing and counseling, participants in the comparison condition will receive risk reduction education and motivational counseling to reduce their risk behaviors.


Ages Eligible for Study:   16 Years to 100 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Of legal age to independently provide written informed consent for research
  • Report having injected drugs at least 12 times in the last three months
  • HIV seronegative (ELISA confirmed)
  • Willing and able to recruit at least three HIV risk network members who are eligible for study participation

Exclusion Criteria:

  • Prior or concurrent enrollment in the last 6 months in another HIV behavioral or biomedical prevention study
  • Psychological disturbance or cognitive impairment that appears to limit the ability to understand study procedures, as determined by clinic staff
  • Any other condition that, in the opinion of the investigator, would make participation in the study unsafe, or otherwise interfere with the study objectives
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00218673

Russian Federation
Biomedical Center
St. Petersburg, Russian Federation, 197110
Sponsors and Collaborators
Johns Hopkins Bloomberg School of Public Health
National Institute on Drug Abuse (NIDA)
Johns Hopkins University
Principal Investigator: Carl Latkin, Ph.D. Johns Hopkins University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Carl Latkin, Professor, Johns Hopkins Bloomberg School of Public Health Identifier: NCT00218673     History of Changes
Other Study ID Numbers: DESPR DA016142
5R01DA016142 ( U.S. NIH Grant/Contract )
Study First Received: September 16, 2005
Last Updated: May 11, 2016

Keywords provided by Carl Latkin, Johns Hopkins Bloomberg School of Public Health:
injection drug use
social networks

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases processed this record on September 20, 2017